Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
The Journal of Clinical Psychiatry
Insights February 17, 2022
Emerging Treatments in Schizophrenia Video
Vol 87 • 2026 • Number 3
Read the Current Issue
Original Research
Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression
Original Research
US Mortality Involving Obesity and Psychiatric Disorders
Academic Highlights
Treatment-Resistant Depression as a Dynamic Continuum: A Consensus Panel Report
Original Research
Effects of Brexpiprazole on Functioning in Patients with Schizophrenia Who Have Hostility and Agitation Symptoms
Original Research
Exposure-Based Video Therapy for OCD and PTSD
Original Research
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Related Articles
Insights
Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video
January 14, 2023
Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...
Insights
Sequencing Therapy in the Treatment of Schizophrenia Video
January 14, 2023
Balancing and optimizing safety and efficacy when treating patients with schizophrenia can be challenging. New approaches to treatment may impact symptoms more effectively and contribute to better adherence. Sequencing,...
